The term “cardiogenic shock market” describes the area of the healthcare sector that offers goods and services to treat cardiogenic shock, a condition in which the heart fails to pump enough blood to meet the body’s demands. Heart attack, heart failure, or other heart-related conditions can all be the root of cardiogenic shock, which is frequently a fatal condition.
The market for products used to treat cardiogenic shock includes inotropes and vasopressors as well as mechanical circulatory support devices like intra-aortic balloon pumps and left ventricular assist devices (LVADs). Companies like Medtronic, Abiomed, St. Jude Medical, and JenaValve Technology are major players in the cardiogenic shock market.
Download Free Sample Copy of this Report – https://www.factmr.com/connectus/sample?flag=S&rep_id=7206
Key Segments Covered in Cardiogenic Shock Industry Research
- Cardiogenic Shock Market by Treatment Type :
- Cardiogenic Shock Treatment Drugs
- Inotropic Agents
- Thrombolytic
- Vasopressors
- Norepinephrine
- Epinephrine
- Vasopressin
- Phenylephrine
- Dobutamine
- Antiplatelet medication
- Other blood-thinning medications
- Cardiogenic Shock Treatment Devices
- Mechanical Circulatory Support (MCS) devices
- Intravascular Micro axial LVAD
- Intra-Aortic Balloon Pump (IABP)
- Axial Flow Pumps
- Extracorporeal Membrane Oxygenation (ECMO)
- Artery Bypass Pumps
- Invasive Ventilation (endotracheal tube)
- In Vitro Test Kits
- N-Terminal Pro-B-Type Natriuretic Peptide (NT-ProBNP)
- Troponin
- Cardiogenic Shock Treatment Drugs
- Cardiogenic Shock Market by End User :
- Hospitals
- Ambulatory Surgical centers
- Cardiac Catheterization Labs
- Office-Based Clinics
- Cardiogenic Shock Market by Region :
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East and Africa (MEA)
Key Takeaways from Market Study
- By treatment type, drugs held the largest share of 52.7% in the global market in 2021, with the segment expected to expand at 7.8% CAGR over the forecast duration.
- By end user, the hospitals segment was valued at US$ 1.33 Bn in 2021.
- North America held the largest share of 36.1% in the global cardiogenic shock treatment market in 2021.
Key Market Players
- ABIOMED
- Bayer AG Abbott
- Viatris
- Par Pharmaceutical
- Getinge Group
- Terumo Corporation
- Medtronic, AstraZeneca
- F. Hoffman-La Roche Ltd
- Others
Competitive Landscape
One of the primary tactics of many market participants is to aggressively collaborate with suppliers that have a strong position and are well-liked in the marketplace through product releases.
- CRMSyncedTM, a teaching application that employs gamification to enable healthcare providers to take a comprehensive approach to treating cardio-renal-metabolic problems, was introduced by Boehringer Ingelheim and Eli Lilly & Company in October 2021.
More Market Insights Available
Fact.MR, in its new offering, presents an unbiased analysis of the cardiogenic shock market, presenting historical demand data (2017-2021) and forecast statistics for the period of 2022-2032.
The study divulges essential insights on the market on the basis of treatment type (drugs [inotropic agents, thrombolytic, vasopressors {norepinephrine, epinephrine, vasopressin, phenylephrine, dobutamine}, antiplatelet medication and other blood-thinning medications], devices [mechanical circulatory support (MCS) devices {intravascular micro axial LVAD, intra‐aortic balloon pump (IABP), axial flow pumps, extracorporeal membrane, artery bypass pumps}, invasive ventilation] and in-vitro test kits [N‐Terminal Pro‐B‐Type Natriuretic Peptide (NT‐ProBNP), Troponin I]), and by end user (hospitals, ambulatory surgical centers, cardiac catheterization labs, and office-based clinics), across seven major regions (North America, Latin America, Europe, East Asia, South Asia, Oceania and the Middle East & Africa)
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
